As of 2026-03-15, the Relative Valuation of Pacira Biosciences Inc (PCRX) is 7.55 USD. This relative valuation is based on P/E multiples. With the latest stock price at 23.26 USD, the upside of Pacira Biosciences Inc based on Relative Valuation is -67.6%.
The range of the Relative Valuation is 3.22 - 12.91 USD.
| Range | Selected | |
| Trailing P/E multiples | 18.8x - 30.8x | 25.9x |
| Forward P/E multiples | 18.2x - 30.4x | 25.1x |
| Fair Price | 3.22 - 12.91 | 7.55 |
| Upside | -86.1% - -44.5% | -67.6% |
| Date | P/E |
| 2026-03-13 | 135.91 |
| 2026-03-12 | 137.49 |
| 2026-03-11 | 133.40 |
| 2026-03-10 | 131.12 |
| 2026-03-09 | 129.95 |
| 2026-03-06 | 128.55 |
| 2026-03-05 | 133.57 |
| 2026-03-04 | 133.57 |
| 2026-03-03 | 129.13 |
| 2026-03-02 | 124.34 |
| 2026-02-27 | 128.02 |
| 2026-02-26 | 131.99 |
| 2026-02-25 | 137.08 |
| 2026-02-24 | 136.79 |
| 2026-02-23 | 135.03 |
| 2026-02-20 | 135.68 |
| 2026-02-19 | 135.44 |
| 2026-02-18 | 134.51 |
| 2026-02-17 | 132.87 |
| 2026-02-13 | 127.20 |
| 2026-02-12 | 125.33 |
| 2026-02-11 | 126.97 |
| 2026-02-10 | 124.11 |
| 2026-02-09 | 123.11 |
| 2026-02-06 | 122.70 |
| 2026-02-05 | 118.96 |
| 2026-02-04 | 120.83 |
| 2026-02-03 | 122.82 |
| 2026-02-02 | 123.99 |
| 2026-01-30 | 120.02 |
| 2026-01-29 | 117.39 |
| 2026-01-28 | 119.08 |
| 2026-01-27 | 115.98 |
| 2026-01-26 | 119.78 |
| 2026-01-23 | 120.78 |
| 2026-01-22 | 121.36 |
| 2026-01-21 | 118.26 |
| 2026-01-20 | 112.77 |
| 2026-01-16 | 111.95 |
| 2026-01-15 | 120.66 |
| 2026-01-14 | 129.95 |
| 2026-01-13 | 126.21 |
| 2026-01-12 | 133.98 |
| 2026-01-09 | 137.49 |
| 2026-01-08 | 152.04 |
| 2026-01-07 | 151.92 |
| 2026-01-06 | 147.89 |
| 2026-01-05 | 146.66 |
| 2026-01-02 | 142.92 |
| 2025-12-31 | 151.22 |